Ascentage Pharma Announces Purchase of 190,000 Shares for 2022 RSU Scheme

On June 10, 2026, Ascentage Pharma Group International announced that the Trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 190,000 existing shares on-market. The shares were acquired to satisfy future RSU vestings under the scheme. The total consideration for the purchase was HK$6,418,500, representing an average price of approximately HK$33.78 per share. This purchase accounts for approximately 0.0509% of the company's total issued shares as of the announcement date. Following this transaction, the total number of existing shares purchased by the Trustee on-market for the 2022 RSU Scheme reached 2,505,000 shares. These shares are held in trust according to the scheme's rules and the trust deed, and the Trustee is prohibited from exercising voting rights associated with these shares. The company noted that this disclosure is made on a voluntary basis and follows several previous grants and share purchases related to the same incentive scheme.